Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.
Br J Haematol
; 121(1): 187-9, 2003 Apr.
Article
em En
| MEDLINE
| ID: mdl-12670352
ABSTRACT
Desferrioxamine (DFX) alone (40-50 mg/kg/d s.c. over 8-12 h, five times weekly) was compared with combined DFX twice weekly and deferiprone (75 mg/kg/d) over 12 months in previously poorly chelated thalassaemia patients. Serum ferritin fell from 5506 +/- 635 microg/l (mean +/- SEM) to 3998 +/- 604 microg/l (P < 0.001; n = 14) in the DFX group and from 4153 +/- 517 microg/l to 2805 +/- 327 microg/l in the combined group (P < 0.01; n = 11). Deferiprone plus DFX produced a greater mean urine iron excretion (1.01 mg/kg/24 h) than iron intake from blood transfusion in each patient. Main side-effects were skin reactions (DFX alone), nausea and arthralgia (combined therapy). As chelation therapy, the combined protocol was as effective as DFX five times weekly.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Piridonas
/
Quelantes
/
Talassemia beta
/
Sobrecarga de Ferro
/
Desferroxamina
/
Ferro
Tipo de estudo:
Clinical_trials
/
Guideline
Idioma:
En
Revista:
Br J Haematol
Ano de publicação:
2003
Tipo de documento:
Article
País de afiliação:
Líbano